



The Course of *Helicobacter pylori* Infection in Pediatric Patients Undergoing Kidney Transplantation

Azizollah Yousefi ¹, Nahid Rahimzadeh ^{1,*}, Rozita Hosseini ², Elahe Norouzi ^{1,**}

¹ Department of Pediatrics, Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Rasoul-e-Akram Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

² Department of Pediatrics, Hazrat-e-Ali Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

*Corresponding Author: Department of Pediatrics, Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Rasoul-e-Akram Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Tel: +98-2164352467; Fax: +98-2166525328, Email: dr_rahimzadeh_ped@yahoo.com

**Corresponding Author: Department of Pediatrics, Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Rasoul-e-Akram Hospital, Pediatric Growth and Development Research Center, Rasoul-e-Akram Medical Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Tel: +98-2164352467; Fax: +98-2166525328, Email: elahe_norouzi@yahoo.com

Received: 23 December, 2024; Revised: 22 April, 2025; Accepted: 24 June, 2025

Abstract

Background: Gastrointestinal complications are common in kidney transplant recipients. In these patients, the use of immunosuppressive drugs reduces the optimal immune response against infections such as *Helicobacter pylori* infection. This study aimed to determine the prevalence of *H. pylori* infection in pediatric kidney transplant patients after transplantation compared to before, and to evaluate the factors related to the rate of infection in these patients.

Methods: Sixty-five kidney transplant patients aged 5 to 18 years were enrolled in the study. Before transplantation, all patients underwent endoscopy. Patients with *H. pylori* infection received eradication treatment, and after transplantation, they were evaluated for *H. pylori* using the urease breath test (UBT). Demographic characteristics, underlying disease, type of drugs used, and duration after transplantation were evaluated. Results: Thirty-eight patients (58.5%) were girls and 27 (41.5%) were boys. Eight patients (12.3%) had *H. pylori* infection before kidney transplantation, and after transplantation, only 2 (3.1%) had a positive UBT. The prevalence of *H. pylori* infection before and after transplantation did not significantly differ between sexes and age groups.

Conclusions: Due to uremia, anemia, and fluctuations in gastric blood supply before transplantation, and the use of immunosuppressive drugs after transplantation, it is recommended to evaluate pediatric renal transplant recipients for *H. pylori* and treat infected patients both before and after kidney transplantation.

Keywords: Kidney Transplantation, *Helicobacter pylori*, End Stage Renal Disease

1. Background

Following kidney transplantation, both infectious and non-infectious gastrointestinal complications such as mouth sores, esophagitis, colitis, peptic ulcers, diarrhea, and even malignancies are likely to occur (1, 2). These complications are common in about half of kidney transplant recipients, with gastritis and peptic ulcers being particularly significant and observed with much greater severity in these patients (3, 4). *Helicobacter pylori*, a gram-negative microaerophilic bacterium that primarily accumulates in the stomach, is

a major cause of chronic gastritis and peptic ulcers and can potentially lead to gastric cancer as well (5). Previous studies indicate a significant relationship between *H. pylori* infection and poor socioeconomic status (6, 7). The overall prevalence of this infection remains more than 30% to 50% (8). In renal transplant recipients, higher rates of gastric and duodenal mucosal lesions and *H. pylori* infection before transplantation may result from higher serum levels of urea, anemia, and fluctuations in gastric blood supply in the chronic renal failure state and during hemodialysis. Furthermore, after transplantation, the use of

immunosuppressive drugs leads to hypogammaglobulinemia and reduces the optimal immune response against infections (9). Therefore, it is necessary to detect *H. pylori* infection before kidney transplantation and evaluate the effect of various treatments to eradicate it in these patients.

2. Objectives

This study aimed to determine the prevalence of *H. pylori* infection in pediatric kidney transplant patients after transplantation compared to before. Additionally, the factors related to the rate of infection in these patients were evaluated.

3. Methods

This was a case series cross-sectional study conducted as a before-and-after evaluation at Rasul-e-Akram and Ali Asghar hospitals in Tehran, Iran. In this study, 65 kidney transplant patients aged between 5 and 18 years were included from 2018 to 2022. Before transplantation, all patients underwent endoscopy, and an antral biopsy was taken to detect *H. pylori*. Patients who had *H. pylori* infection received eradication treatment; all transplanted patients were negative for *H. pylori* infection. Sequential therapy for *H. pylori* infection consisted of a proton pump inhibitor (PPI) plus amoxicillin for the first week, followed by a PPI plus metronidazole and clarithromycin for the second week. One to eight years after kidney transplantation, all patients were evaluated for *H. pylori* infection using the Urease Breath Test (UBT). A questionnaire was completed for all patients, including demographic characteristics, the type of disease that led to the transplant, the type of drugs used, and the duration after the transplant. Written consent was obtained from the parents and patients participating in the study. SPSS Statistics version 26 was used for statistical analyses. Descriptive variables were expressed as numbers and percentages; mean numeric variables were expressed as mean \pm standard deviation (SD). The Mann-Whitney U test was used for comparisons before and after transplantation. The difference between categorical variables was tested with the chi-square (χ^2) test. A P-value of less than 0.05 was considered statistically significant. The research was approved by the ethics committee of Iran University of

Medical Sciences with the code number [IR.IUMS.REC.1397.785](#) and was conducted in accordance with the Helsinki Declaration.

4. Results

Among the 65 pediatric kidney transplant patients who participated in the study, 38 (58.5%) were girls and 27 (41.5%) were boys. Regarding the underlying diseases leading to renal transplant, the most common was reflux nephropathy with neurogenic bladder in 16 patients (24.61%). This was followed by hypoplastic kidney disease (21.53%), familial focal segmental glomerulosclerosis (FSGS) (21.53%), undetermined causes (21.53%), cystinosis (4.61%), nephronophthisis (4.61%), congenital nephrotic syndrome (3.07%), and autosomal recessive polycystic kidney disease (3.07%). The least common underlying diseases leading to kidney transplant were renal tubular acidosis (RTA), Alport syndrome, and chronic glomerulonephritis, each occurring in one patient (1.53%).

Before kidney transplantation, only one patient had not undergone dialysis. Of the other 64 patients, 29 (44.6%) had undergone hemodialysis, 16 (24.6%) had experienced peritoneal dialysis, and 19 (29.2%) had undergone both hemodialysis and peritoneal dialysis. In terms of the immunosuppressive drug regimen to prevent transplant rejection, all patients (100%) received mycophenolate mofetil (MMF). Additionally, 64 patients (98.46%) received tacrolimus, while only one patient (1.53%) received cyclosporine (Sandimmun) due to the occurrence of diabetes mellitus.

The two patients with positive UBT results after transplantation were new cases of *H. pylori* infection, and both received MMF and tacrolimus as immunosuppressive drugs. The duration since kidney transplantation varied from 1 to 8 years, with the majority of cases (23.07%) evaluated two years post-transplant for *H. pylori*, and only one patient (1.53%) evaluated 7 and 8 years post-transplant. The duration of dialysis before transplantation was less than one month in 22 patients, more than 36 months in 11 cases, and between 1 to 36 months in the remaining patients ([Table 1](#)).

Table 1. Demographic Data of Pediatrics Patients of Renal Transplant

Parameters	No. (%)
Gender	
Female	38 (58.5)
Male	27 (41.5)
Age (y)	
4 - 8	16 (24.6)
9 - 13	34 (52.3)
14 - 18	23.1 (15)
Weight (kg)	
15 - 29	29 (44.6)
30 - 44	28 (43.1)
45 - 60	8 (12.3)
Dialysis	
Hemodialysis	29 (44.6)
Peritoneal	16 (24.6)
Hemo-peritoneal	19 (29.2)
None	1 (1.5)
Immunosuppressive drug	
MMF + Cyclosporine	1 (1.5)
MMF + Tacrolimus	64 (98.4)

Out of 65 patients evaluated before transplantation by antral biopsy, 8 had *H. pylori* infection, resulting in a prevalence of 12.3%. After transplantation, only 2 (3.1%) had a positive UBT. The prevalence of *Helicobacter* infection before and after transplantation did not show a significant difference between sexes, with p-values of 0.301 and 0.644, respectively. Additionally, there was no relationship between age and the presence of *Helicobacter* infection before and after kidney transplantation, with P-values of 0.547 and 0.474, respectively.

5. Discussion

In this study, the incidence of *H. pylori* infection in pediatric renal transplant patients was 3.1% after transplantation and 12.3% before transplantation. A study by Cheungpasitporn et al. showed that between 1990 and 2000, the estimated prevalence of *H. pylori* infection in transplant patients was 50%, with 46% in developed countries and 55% in developing countries. Between 2000 and 2016, the incidence of infection decreased to 35%, with 28% in developed countries and 45% in developing countries. In general, the relative risk of infection in transplant patients was reported as 0.57 (10).

In the study by Bunchorntavakul et al., 107 patients with end-stage renal disease were evaluated. Positive esophagogastrosopic findings were observed in 46% of

patients, mainly in the form of erosive gastroduodenitis and peptic ulcers. The prevalence of *H. pylori* infection in these patients was 27.1% (11).

In the study by Hooman et al. in 2011, data from 117 children aged 5 to 18 years with end-stage renal disease who underwent renal transplantation were evaluated. Gastrointestinal symptoms were reported in 12% of children, and *H. pylori* infection was reported in 24% of children (12).

In the study by Cocchiara et al., patients with ESRD who were candidates for kidney transplantation underwent esophagogastroduodenoscopic evaluation to rule out *H. pylori* infection. In total, 32 patients were affected by *H. pylori* infection (52.4%) (13).

In a multicenter prospective cohort study on adult chronic kidney disease patients, Maioli et al. demonstrated a high prevalence (61.4%) of *H. pylori* and a low eradication rate after long-term treatment (48.5%). However, in our study, the total prevalence of *H. pylori* was lower (12.3%), and the eradication rate was higher (14). The prevalence of *H. pylori* in our study decreased after transplantation despite immunosuppressive treatment. Higher rates of *H. pylori* infection before transplantation may have resulted from higher serum levels of urea, anemia, and fluctuations in gastric blood supply in the chronic renal failure state and hemodialysis. The decreased rate of *H. pylori* infection after transplantation in this study is related to the correction of the uremic state and anemia and improved gastric blood supply.

In another study conducted on 61 adult renal transplant candidates in Turkey, 14% of patients were *H. pylori* positive. The infection was closely associated with the presence of peptic ulcers in these patients' endoscopy (15).

5.1. Conclusions

Due to uremia, anemia, and fluctuations in gastric blood supply before transplantation, and the use of immunosuppressive drugs after transplantation, it is recommended to evaluate pediatric renal transplant recipients for *H. pylori* and treat infected patients both before and after kidney transplantation.

Footnotes

Authors' Contribution: Study concept and design: A. Y. and N. R.; Acquisition of data: A. Y. and N. R.; Analysis and interpretation of data: A. Y. and R. H.; Drafting of the manuscript: E. N.

Conflict of Interests Statement: The authors declare no conflict of interests.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to ethics.

Ethical Approval: The research was approved primarily by ethics committee of Iran University of Medical Sciences with code number of [IR.IUMS.REC.1397.785](#) and carried out in accordance with the Helsinki Declaration.

Funding/Support: This study was not supported financially nor received any grant.

Informed Consent: Written consent were obtained from the patients.

References

1. Telkes G, Peter A, Tulassay Z, Asderakis A. High frequency of ulcers, not associated with *Helicobacter pylori*, in the stomach in the first year after kidney transplantation. *Nephrol Dial Transplant*. 2011;**26**(2):727-32. [PubMed ID: [20603242](#)]. <https://doi.org/10.1093/ndt/gfq401>.
2. Gil-Vernet S, Amado A, Ortega F, Alarcon A, Bernal G, Capdevila L, et al. Gastrointestinal complications in renal transplant recipients: MITOS study. *Transplant Proc*. 2007;**39**(7):2190-3. [PubMed ID: [17889134](#)]. <https://doi.org/10.1016/j.transproceed.2007.07.015>.
3. Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. *Transpl Int*. 2005;**18**(6):643-50. [PubMed ID: [15910287](#)]. <https://doi.org/10.1111/j.1432-2277.2005.00134.x>.
4. de Francisco AL. Gastrointestinal disease and the kidney. *Eur J Gastroenterol Hepatol*. 2002;**14 Suppl 1**:S11-5. [PubMed ID: [12570024](#)].
5. Wijarnpreecha K, Thongprayoon C, Nissaisorakarn P, Jaruvongvanich V, Nakkala K, Rajapakse R, et al. Association of *Helicobacter pylori* with chronic kidney diseases: a meta-analysis. *Digestive diseases and sciences*. 2017;**62**:2045-52.
6. Yousefi A, Eslami S, Noorbakhsh S, Haghighi M, TaheriNia L, Ehsanipour F, et al. The Resistance Rate of *Helicobacter Pylori* to Clarithromycin and Main Mutations on Bacterial Genomic Responsible for Bacterial Resistance: A Comparative Study in Children and Adults, Tehran and Iran. *Infect Disord Drug Targets*. 2019;**19**(4):394-7. [PubMed ID: [30318006](#)]. <https://doi.org/10.2174/1871526518666181012113052>.
7. Khedmat H, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, et al. Gastro-duodenal lesions and *Helicobacter pylori* infection in uremic patients and renal transplant recipients. *Transplant Proc*. 2007;**39**(4):1003-7. [PubMed ID: [17524875](#)]. <https://doi.org/10.1016/j.transproceed.2007.03.034>.
8. Abbasi Larki R, Azad A, Jannesar R, Manzouri L, Jahanbani S. The Effect of *Helicobacter Pylori* Infection Eradication on Glomerular Filtration Rate in Patients with Chronic Kidney Disease. *Journal of Clinical Care and Skills*. 2024;**5**(3):145-50.
9. Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. *Am J Transplant*. 2013;**13**(10):2601-10. [PubMed ID: [23919557](#)]. <https://doi.org/10.1111/ajt.12401>.
10. Cheungpasitporn W, Thongprayoon C, Wijarnpreecha K, Mitema DG, Mao MA, Nissaisorakarn P, et al. Decline in prevalence and risk of *Helicobacter pylori* in kidney transplant recipients: A systematic review and meta-analysis. *J Evid Based Med*. 2017;**10**(3):171-6. [PubMed ID: [28464553](#)]. <https://doi.org/10.1111/jebm.12252>.
11. Bunchorntavakul C, Atsawarungruangkit A. Prevalence of asymptomatic gastroduodenal lesions and *Helicobacter pylori* infection in kidney transplant candidates. *J Med Assoc Thai*. 2014;**97 Suppl 11**:S62-8. [PubMed ID: [25509697](#)].
12. Hooman N, Mehrzama M, Talachian E, Otukesh H, Nakhaii S. *Helicobacter pylori* infection in pediatric candidates for kidney transplantation. *Iran J Kidney Dis*. 2011;**5**(2):124-9. [PubMed ID: [21368392](#)].
13. Cocchiara G, Romano M, Buscemi G, Maione C, Maniaci S, Romano G. Advantage of eradication therapy for *Helicobacter pylori* before kidney transplantation in uremic patients. *Transplant Proc*. 2007;**39**(10):3041-3. [PubMed ID: [18089317](#)]. <https://doi.org/10.1016/j.transproceed.2007.07.095>.
14. Maioli ME, Frange RFN, Grion CMC, Delfino VDA. *Helicobacter pylori* eradication in renal transplant candidates. *J Bras Nefrol*. 2022;**44**(2):215-23. [PubMed ID: [35014666](#)]. [PubMed Central ID: [PMC9269173](#)]. <https://doi.org/10.1590/2175-8239-JBN-2021-0097>.
15. Savas N. *Helicobacter pylori* prevalence and its association with endoscopic findings in renal transplant candidates. *Akademik gastroenteroloji dergisi*. 2014;**13**(3):79-82.